Clinical Trials
3 trialsNCT02991456 2023-07-11
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Duke University
Phase 2 Completed
NCT01450826 2018-06-26
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
Phase 2 Completed
NCT01952886 2014-09-22
Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients
Duke University
Phase 2 Withdrawn